G
Geraldine Horigan
Researcher at Ulster University
Publications - 42
Citations - 1186
Geraldine Horigan is an academic researcher from Ulster University. The author has contributed to research in topics: Methylenetetrahydrofolate reductase & Vitamin D and neurology. The author has an hindex of 13, co-authored 40 publications receiving 1034 citations. Previous affiliations of Geraldine Horigan include University College Cork & Altnagelvin Area Hospital.
Papers
More filters
Journal ArticleDOI
Estimation of the dietary requirement for vitamin D in healthy adults
Kevin D. Cashman,Tom R. Hill,Alice J. Lucey,Nicola Taylor,Kelly M. Seamans,S Muldowney,Anthony P. Fitzgerald,Albert Flynn,Maria S. Barnes,Geraldine Horigan,Maxine P. Bonham,Emeir M. Duffy,J. J. Strain,Julie M. W. Wallace,Mairead Kiely +14 more
TL;DR: The range of vitamin D intakes required to ensure maintenance of wintertime vitamin D status in the vast majority of 20-40-y-old adults, considering a variety of sun exposure preferences, is between 7.2 and 41.1 microg/d.
Journal ArticleDOI
Estimation of the dietary requirement for vitamin D in free-living adults ≥64 y of age
Kevin D. Cashman,Julie M. W. Wallace,Geraldine Horigan,Tom R. Hill,Maria S. Barnes,Alice J. Lucey,Maxine P. Bonham,Nicola Taylor,Emeir M. Duffy,Kelly M. Seamans,S Muldowney,Anthony P. Fitzgerald,Albert Flynn,J. J. Strain,Mairead Kiely +14 more
TL;DR: To ensure that the vitamin D requirement is met by the vast majority of adults aged >/=64 y during winter, between 7.9 and 42.8 microg vitamin D/d is required, depending on summer sun exposure and the threshold of adequacy of 25(OH)D.
Journal ArticleDOI
Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review.
TL;DR: To identify the reasons why those offered a place on diabetes education programmes declined the opportunity, a database of more than 1,000 patients from around the world was constructed.
Journal ArticleDOI
Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR.
TL;DR: Riboflavin is effective in reducing blood pressure specifically in patients with the MTHFR 677 TT genotype, and may have important implications for the prevention and treatment of hypertension.
Journal ArticleDOI
Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up
Carol P Wilson,Mary Ward,Helene McNulty,James J. Strain,Tom G. Trouton,Geraldine Horigan,John Purvis,John M. Scott +7 more
TL;DR: Optizing riboflavin status offers a low-cost targeted strategy for managing elevated BP in this genetically at-risk group, and could have important implications for the prevention of hypertension.